Cobenfy Beyond Psychosis: What is the Potential of Muscarinics to Address the High Unmet Need for Cognitive & Negative Symptom Management?
Time: 5:00 pm
day: Day One PM
Details:
- Exploring promising avenues for Cobenfy to target symptoms beyond psychosis
- Outlining future directions for Cobenfy to be investigated for negative schizophrenia symptoms and cognitive-related symptoms across psychiatry: how could it be used to achieve functional recovery?
- Addressing key obstacles to anticipate and address when targeting negative symptoms and cognitive deficits in clinical populations
